Company: RCUS
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001724521-25-000052
Chunk: 67

Company: Arcus Biosciences, Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 67
---
 will pay to us tiered royalties as a percentage of revenues ranging from the high teens to the low twenties. Further, with respect to domvanalimab, we remain eligible to receive up to $500 million in milestone payments. During the year ended December 31, 2024, we have recorded $137 million in gross cost-sharing payments from Gilead under the Gilead Collaboration Agreement. During the year ended December 31, 2024, we have incurred $100 million due to Gilead pursuant to our cost-sharing obligations.

• Common Stock Purchase Agreement : In 2020, we entered into a Common Stock Purchase Agreement with Gilead (as amended, the "Purchase Agreement"). Under the Purchase Agreement, Gilead has the right, at its option, to purchase additional shares from us, up to a maximum ownership of 35% of our then-outstanding voting common stock, from time to time until July 2025, at a purchase price per share equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead exercises such option, and the $33.54 initial purchase price per share. Since January 1, 2024, Gilead has purchased 15.2 million shares for an aggregate purchase price of $320 million under the Purchase Agreement.

• Investor Rights Agreement : In 2020, we entered into an Investor Rights Agreement with Gilead (as amended, the "Investor Rights Agreement"). The Investor Rights Agreement provides Gilead with registration rights, pro rata participation rights in certain future financings and the right to designate three individuals, which they have exercised, to be appointed to our board of directors. Gilead’s current director designees are Dr. Berger, Dr. Higgins and Ms. Mercier. Pursuant to the Investor Rights Agreement, we established a Science Committee and Drs. Berger and Higgins are members of our Science Committee.

• Participation in Our Underwritten Equity Offering : In February 2025, we sold through an underwritten offering, 13.6 million shares of our common stock at a price of $11.00 per share, for

<div align='center'>40.</div>

total gross proceeds of approximately $150 million, before deducting underwriting discounts, commissions and offering expenses. Gilead acquired shares in this offering from the underwriters for an aggregate purchase price of $15 million. As of February 19, 2025